Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
30685-43-9
Molecular formula
C42H66O14
Molecular weight
795 g/mol
Drug class
Cardiac glycosidecardiotonic and antiarrhythmic agent
Mechanism of action
Inhibits myocardial Na+/K+-ATPase, increasing intracellular sodium and indirectly increasing intracellular calcium through reduced sodium-calcium exchange. This increases myocardial contractility and also enhances vagal tone, slowing atrioventricular conduction. Metildigoxin is demethylated to digoxin.
Indications / reported uses
Historical and jurisdiction-specific use for symptomatic treatment of selected cases of chronic heart failure and supraventricular arrhythmias, including atrial fibrillation; product availability and current use vary by country.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Metildigoxin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Metildigoxin Permitted Daily Exposure (PDE) report (the Metildigoxin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Metildigoxin Occupational Exposure Limit (OEL) report (the Metildigoxin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.